The DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.
Immune checkpoint inhibitors in challenging populations
Open accessAbstract
Immune checkpoint inhibitors, including those targeting the programmed cell death 1/programmed cell death ligand 1 and cytotoxic T lymphocyte antigen 4 pathways, are revolutionizing cancer therapeutics. Both activity and toxicities largely stem from unleashing tumor- or host-specific cytotoxic T cells. Many patients seen in routine clinical practice have not qualified for or have been seriously underrepresented in immune checkpoint inhibitor clinical trials. Thus, a major gap in knowledge regarding the safety and efficacy of these agents persists in many populations, even after regulatory approval. To address this challenge, this review aggregates and synthesizes the available preclinical and clinical data surrounding immune checkpoint inhibitor therapy in challenging clinical populations to assist both academic and community oncologists in treatment decision making. Specifically, this review focuses on the safety and activity of immune checkpoint inhibitors in patients with autoimmune disorders, organ transplant patients, patients with chronic viral infections, patients with ongoing immunosuppressant use, patients with organ dysfunction, pregnant patients, patients with brain metastases, patients at extremes of age, and patients with an impaired functional status. Cancer 2017;123:1904-1911. © 2017 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Thus, the safety and effectiveness of ICI therapy in this special population are unknown.34”
From Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: Review of the literature and personalized risk-based prevention strategy (2020) · cites this paper as [34]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Kaur, A., Webster, M. R., Marchbank, K., Behera, R., Ndoye, A., Kugel, C. H., Dang, V. M., Appleton, J., O’Connell, M. P., Cheng, P., et al. (2016) · Nature · doi:10.1038/nature17392 · Cited by 398
Self-citationRetractedPD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Rosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00561-4 · Cited by 3,669
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Ansell, S. M., Lesokhin, A. M., Borrello, I., Halwani, A. S., Scott, E. C., Gutierrez, M. E., Schuster, S. J., Millenson, M. M., Cattry, D., Freeman, G. J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1411087 · Cited by 3,621
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
Weber, J. S., D’Angelo, S. P., Minor, D. R., Hodi, F. S., Gutzmer, R., Neyns, B., Höeller, C., Khushalani, N. I., Miller, W. H., Lao, C. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70076-8 · Cited by 2,725
PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression
Day, C. L., Kaufmann, D. E., Kiepiela, P., Brown, J. A., Moodley, E. S., Reddy, S., Mackey, E. W., Miller, J. D., Leslie, A. J., DePierres, C., et al. (2006) · Nature · doi:10.1038/nature05115 · Cited by 2,680
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
Johnson, D. B., Balko, J. M., Compton, M. L., Chalkias, S., Gorham, J., Xu, Y., Hicks, M., Puzanov, I., Alexander, M. R., Bloomer, T. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609214 · Cited by 2,308
Self-citationBalar, A. V., Galsky, M. D., Rosenberg, J. E., Powles, T., Petrylak, D. P., Bellmunt, J., Loriot, Y., Necchi, A., Hoffman-Censits, J., Perez-Gracia, J. L., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32455-2 · Cited by 2,199
Ribas, A., Puzanov, I. J., Dummer, R., Schadendorf, D., Hamid, O., Robert, C., Hodi, F. S., Schachter, J., Pavlick, A. C., Lewis, K. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00083-2 · Cited by 1,590
Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction
Trautmann, L., Janbazian, L., Chomont, N., Said, E. A., Gimmig, S., Bessette, B., Boulassel, M.-R., Delwart, E., Sepulveda, H., Balderas, R. S., et al. (2006) · Nature Medicine · doi:10.1038/nm1482 · Cited by 1,565
PD-1 Blockade with pembrolizumab in advanced Merkel-cell carcinoma
Nghiem, P. T., Bhatia, S., Lipson, E. J., Kudchadkar, R. R., Miller, N. J., Annamalai, L., Berry, S., Chartash, E. K., Daud, A., Fling, S. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603702 · Cited by 1,258
Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
Margolin, K., Ernstoff, M. S., Hamid, O., Lawrence, D., McDermott, D., Puzanov, I., Wolchok, J. D., Clark, J. I., Sznol, M., Logan, T. F., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70090-6 · Cited by 1,091
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
Ribas, A., Hamid, O., Daud, A., Hodi, F. S., Wolchok, J. D., Kefford, R., Joshua, A. M., Patnaik, A., Hwu, W.-J., Weber, J. S., et al. (2016) · JAMA · doi:10.1001/jama.2016.4059 · Cited by 1,069
Participation of Patients 65 Years of Age or Older in Cancer Clinical Trials
Lewis, J. H., Kilgore, M. L., Goldman, D. P., Trimble, E. L., Kaplan, R. S., Montello, M. J., Housman, M. G., & Escarce, J. J. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.08.010 · Cited by 1,029
Goldberg, S. B., Gettinger, S. N., Mahajan, A. K., Chiang, A. C., Herbst, R. S., Sznol, M., Tsiouris, A. J., Cohen, J. V., Vortmeyer, A. O., Jilaveanu, L. B., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30053-5 · Cited by 1,003
Menzies, A. M., Johnson, D. B., Ramanujam, S., Atkinson, V. G., Wong, A. N. M., Park, J. J., McQuade, J. L., Shoushtari, A. N., Tsai, K. K., Eroglu, Z., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw443 · Cited by 817
Prokunina‐Olsson, L., Castillejo-López, C., Oberg, F. G., Gunnarsson, I., Berg, L., Magnusson, V., Brookes, A. J., Tentler, D., Kristjansdóttir, H., Gröndal, G., et al. (2002) · Nature Genetics · doi:10.1038/ng1020 · Cited by 770
Chemotherapy Use, Performance Status, and Quality of Life at the End of Life
Prigerson, H. G., Bao, Y., Shah, M. A., Paulk, M. E., LeBlanc, T. W., Schneider, B. J., Garrido, M. M., Reid, M. C., Berlin, D., Adelson, K. B., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.2378 · Cited by 648
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
Johnson, D. B., Sullivan, R. J., Ott, P. A., Carlino, M. S., Khushalani, N. I., Ye, F., Guminski, A., Puzanov, I., Lawrence, D. P., Buchbinder, E. I., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.4368 · Cited by 642
Self-citationIpilimumab for Patients with Relapse after Allogeneic Transplantation
Davids, M. S., Kim, H. T., Bachireddy, P., Costello, C. L., Liguori, R., Savell, A., Lukez, A. P., Avigan, D., Chen, Y., McSweeney, P. A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1601202 · Cited by 595
Prognostic Factors for Survival in Patients With Inoperable Lung Cancer 2
Stanley, K. (1980) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/65.1.25 · Cited by 561
Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy
Heinzerling, L., Ott, P. A., Hodi, F. S., Husain, A. N., Tajmir-Riahi, A., Tawbi, H., Pauschinger, M., Gajewski, T. F., Lipson, E. J., & Luke, J. J. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0152-y · Cited by 511
Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade
Johnson, D. B., Frampton, G. M., Rioth, M. J., Yusko, E., Xu, Y., Guo, X., Ennis, R. C., Fabrizio, D., Chalmers, Z. R., Greenbowe, J., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0143 · Cited by 481
Bashey, A., Medina, B., Corringham, S., Pasek, M., Carrier, E., Vrooman, L., Lowy, I., Solomon, S., Morris, L., Holland, H., et al. (2009) · Blood · doi:10.1182/blood-2008-07-168468 · Cited by 343
Wright, A. A., Zhang, B., Keating, N. L., Weeks, J. C., & Prigerson, H. G. (2014) · BMJ · doi:10.1136/bmj.g1219 · Cited by 340
Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors
Merchant, M. S., Wright, M., Baird, K., Wexler, L. H., Rodriguez-Galindo, C., Bernstein, D., Delbrook, C., Lodish, M., Bishop, R., Wolchok, J. D., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0491 · Cited by 331
Nishijima, T. F., Muss, H. B., Shachar, S. S., & Moschos, S. J. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.02.006 · Cited by 293
Tumor Regression and Allograft Rejection after Administration of Anti–PD-1
Lipson, E. J., Bagnasco, S. M., Moore, J. D., Jang, S., Patel, M. J., Zachary, A. A., Pardoll, D. M., Taube, J. M., & Drake, C. G. (2016) · New England Journal of Medicine · doi:10.1056/nejmc1509268 · Cited by 278
Ahmed, K. A., Stallworth, D. G., Kim, Y., Johnstone, P. A. S., Harrison, L. B., Caudell, J. J., Yu, H., Etame, A. B., Weber, J. S., & Gibney, G. T. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv622 · Cited by 240
Induction of autoimmune disease by deletion of CTLA-4 in mice in adulthood
Klocke, K., Sakaguchi, S., Holmdahl, R., & Wing, K. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1603892113 · Cited by 234
Tanaka, K., Albin, M. J., Yuan, X., Yamaura, K., Habicht, A., Murayama, T., Grimm, M. R., Waaga, A. M., Ueno, T., Padera, R. F., et al. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.8.5204 · Cited by 208
Hadji, P., Coleman, R., Wilson, C., Powles, T. J., Clézardin, P., Aapro, M., Costa, L., Body, J., Markopoulos, C. J., Santini, D., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv617 · Cited by 208
El-Khoueiry, A. B., Melero, I., Crocenzi, T. S., Welling, T. H., Yau, T. C., Yeo, W., Chopra, A., Grosso, J. F., Lang, L., Anderson, J., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.18_suppl.lba101 · Cited by 195
Mould, D. R., & Sweeney, K. (2007) · PubMed · Cited by 172
The Link between the PDL1 Costimulatory Pathway and Th17 in Fetomaternal Tolerance
D’Addio, F., Riella, L. V., Mfarrej, B. G., Chabtini, L., Adams, L. T., Yeung, M. Y., Yagita∥, H., Azuma, M., Sayegh, M. H., & Guleria, I. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1002031 · Cited by 172
Prevalence of Autoimmune Disease Among Patients With Lung Cancer
Khan, S. A., Pruitt, S. L., Xuan, L., & Gerber, D. E. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.2238 · Cited by 164
Lipson, E. J., Bodell, M. A., Kraus, E. S., & Sharfman, W. H. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.2314 · Cited by 158
Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma
Liniker, E., Menzies, A. M., Kong, B. Y., Cooper, A. J., Ramanujam, S., Lo, S., Kefford, R. F., Fogarty, G. B., Guminski, A. D., Wang, W., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1214788 · Cited by 154
Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma
Spain, L. A., Higgins, R. M., Gopalakrishnan, K., Turajlic, S., Gore, M. E., & Larkin, J. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw130 · Cited by 145
Wolchok, J. D. (2015) · Cell · doi:10.1016/j.cell.2015.07.045 · Cited by 139
Safety and efficacy of ipilimumab to treat advanced melanoma in the setting of liver transplantation
Morales, R. E., Shoushtari, A. N., Walsh, M. M., Grewal, P., Lipson, E. J., & Carvajal, R. D. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0066-0 · Cited by 110
PD-1 Blockade in Advanced Melanoma in Patients with Hepatitis C and/or HIV
Davar, D., Wilson, M. A., Pruckner, C., & Kirkwood, J. M. (2015) · Case Reports in Oncological Medicine · doi:10.1155/2015/737389 · Cited by 103
Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient
Herz, S., Höfer, T., Papapanagiotou, M., Leyh, J., Meyenburg, S., Schadendorf, D., Ugurel, S., Roesch, A., Livingstone, E., Schilling, B., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.07.026 · Cited by 102
Poulet, F. M., Wolf, J. J., Herzyk, D. J., & DeGeorge, J. J. (2016) · Birth Defects Research Part B Developmental and Reproductive Toxicology · doi:10.1002/bdrb.21176 · Cited by 98
Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality
Saha, A., O’Connor, R. S., Thangavelu, G., Lovitch, S. B., Dandamudi, D. B., Wilson, C. B., Vincent, B. G., Tkachev, V., Pawlicki, J. M., Furlan, S. N., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85796 · Cited by 96
Administration of Ipilimumab to a Liver Transplant Recipient With Unresectable Metastatic Melanoma
Ranganath, H., & Panella, T. J. (2015) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000077 · Cited by 94
Low Frequency of Programmed Death Ligand 1 Expression in Pediatric Cancers
Aoki, T., Hino, M., Koh, K., Kyushiki, M., Kishimoto, H., Arakawa, Y., Hanada, R., Kawashima, H., Kurihara, J., Shimojo, N., et al. (2016) · Pediatric Blood & Cancer · doi:10.1002/pbc.26018 · Cited by 90
Shi, X., Mancham, S., Hansen, B. E., de Knegt, R. J., de Jonge, J., van der Laan, L. J. W., Rivadeneira, F., Metselaar, H. J., & Kwekkeboom, J. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.02.034 · Cited by 86
Use of the PD-1 Pathway Inhibitor Nivolumab in a Renal Transplant Patient With Malignancy
Boils, C. L., Aljadir, D., & Cantafio, A. W. (2016) · American Journal of Transplantation · doi:10.1111/ajt.13786 · Cited by 82
Antitumor activity of nivolumab on hemodialysis after renal allograft rejection
Ong, M., Ibrahim, A. M., Bourassa‐Blanchette, S., Canil, C., Fairhead, T., & Knoll, G. A. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0171-8 · Cited by 81
Systemic Immunotherapy for the Treatment of Brain Metastases
Cohen, J. V., & Kluger, H. M. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00049 · Cited by 78
Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction
Kanz, B. A., Pollack, M. H., Johnpulle, R., Puzanov, I., Horn, L., Morgans, A., Sosman, J. A., Rapisuwon, S., Conry, R. M., Eroglu, Z., et al. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0166-5 · Cited by 75
Self-citationFatal GvHD induced by PD-1 inhibitor pembrolizumab in a patient with Hodgkin’s lymphoma
Singh, A. K., Porrata, L. F., Aljitawi, O. S., Lin, T. L., Shune, L. O., Ganguly, S., McGuirk, J. P., & Abhyankar, S. (2016) · Bone Marrow Transplantation · doi:10.1038/bmt.2016.111 · Cited by 72
Lukens, J. R., Cruise, M. W., Lassen, M. G., & Hahn, Y. S. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.7.4875 · Cited by 62
Owonikoko, T. K., Kumar, M., Yang, S., Kamphorst, A. O., Pillai, R. N., Akondy, R. S., Nautiyal, V., Chatwal, M. S., Book, W., Sahu, A., et al. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1918-2 · Cited by 61
Yared, J. A., Hardy, N. M., Singh, Z. N., Hajj, S., Badros, A. Z., Kocoglu, M. H., Yanovich, S., Sausville, E. A., Ujjani, C. S., Ruehle, K., et al. (2016) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.346 · Cited by 56
Villasboas, J. C., Ansell, S. M., & Witzig, T. E. (2016) · Oncotarget · doi:10.18632/oncotarget.7177 · Cited by 55
Nivolumab in a patient with refractory Hodgkin’s lymphoma after allogeneic stem cell transplantation
Angenendt, L., Schliemann, C., Lutz, M., Rebber, E., Schulze, A. B., Weckesser, M., Stegger, L., Schäfers, M. A., Groth, C., Keßler, T., et al. (2015) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.266 · Cited by 54
José, A. D. L. F. H., Yiannoullou, P., Bhutani, S., Denley, H., Morton, M., Picton, M. L., Summers, A., van Dellen, D., & Augustine, T. (2016) · Transplantation Proceedings · doi:10.1016/j.transproceed.2016.07.019 · Cited by 53
Salloum, R. G., Smith, T. J., Jensen, G. A., & Lafata, J. E. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.04.019 · Cited by 51
Possible Interaction of Anti–PD-1 Therapy with the Effects of Radiosurgery on Brain Metastases
Alomari, A. K., Cohen, J. V., Vortmeyer, A. O., Chiang, A. C., Gettinger, S. N., Goldberg, S. B., Kluger, H. M., & Chiang, V. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0238 · Cited by 51
Chan, T. S. Y., Khong, P., & Kwong, Y. (2016) · Annals of Hematology · doi:10.1007/s00277-016-2764-1 · Cited by 51
Jeong, H.-Y., Lee, Y.-J., Seo, S., Lee, S.-W., Park, S. J., Lee, J.-N., Sohn, H., Yao, S., Chen, L., & Choi, I. (2007) · Journal of Leukocyte Biology · doi:10.1189/jlb.0307168 · Cited by 48
Ring, E. K., Markert, J. M., Gillespie, G. Y., & Friedman, G. K. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1829 · Cited by 45
Responses to immune checkpoint inhibitors in nonagenarians
Johnpulle, R. A. N., Conry, R. M., Sosman, J. A., Puzanov, I. J., & Johnson, D. B. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1234572 · Cited by 27
Shad, A. T., Huo, J. S., Darcy, C. T., Abu‐Ghosh, A., Esposito, G., Holuba, M. J., Robey, N. C., Cooke, K. R., Symons, H. J., Chen, A. R., et al. (2016) · Pediatric Blood & Cancer · doi:10.1002/pbc.26257 · Cited by 22
Schade, H. H., Sen, S., Neff, C. P., Freed, B. M., Gao, D., Gutman, J. A., & Palmer, B. E. (2016) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2016.08.007 · Cited by 19
Safety and efficacy of anti-PD-1 antibodies in elderly patients with metastatic melanoma
Rai, R., McQuade, J. L., Wang, D. Y., Park, J., Nahar, K. J., Sosman, J. A., Beckermann, K. E., Haydu, L. E., Lo, S., Rubinstein, S. M., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw379.08 · Cited by 15
Forconi, C. S., Gatault, P., Miquelestorena‐Standley, E., Noble, J., Al-Hajj, S., Guillemain, R., Stern, M., Hoffmann, T., Prat, L., Suberbielle, C., et al. (2016) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2016.08.014 · Cited by 14
A Retrospective Analysis of the Efficacy of Pembrolizumab in Melanoma Patients With Brain Metastasis
Dagogo‐Jack, I., Lanfranchi, M., Gainor, J. F., Giobbie‐Hurder, A., Lawrence, D. P., Shaw, A. T., & Sullivan, R. J. (2017) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000159 · Cited by 13
Safety of pembrolizumab after allogeneic haematopoietic stem cell transplantation
Kwong, Y. (2016) · Annals of Hematology · doi:10.1007/s00277-016-2651-9 · Cited by 12
Aslan, A., Aras, T., & Özdemir, E. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1213835 · Cited by 11
小児T細胞充足,ハプロタイプ一致骨髄移植後のnivolumabの忍容性と有効性:症例報告【Powered by NICT】
Aziza, T. S., Jeffrey, S., Darcy, C. T., Abu‐Ghosh, A., Esposito, G., Holuba, M. J., Robey, N. C., Kenneth, R. C., Heather, J. S., Allen, R., et al. (2017) · Pediatric Blood & Cancer · Cited by 3
Flagged first, then by citations
Research works printed but not linked: 1
- Bethof A, 2015, Age on outcome and toxicity with anti–PD‐1/PD‐L1 therapy in patients with melanoma [abstract], Pigment Cell Melanoma Res, 28, 756
Cited by
Sorted by citations
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1703481 · Cited by 4,849
Immune-related adverse events of checkpoint inhibitors
Ramos‐Casals, M., Brahmer, J. R., Callahan, M. K., Flores-Chávez, A., Keegan, N. M., Khamashta, M. A., Lambotte, O., Mariette, X., Prat, A., & Suarez-Almazor, M. E. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0160-6 · Cited by 1,491
Evolving therapeutic landscape of advanced hepatocellular carcinoma
Yang, C. G., Zhang, H., Zhang, L., Zhu, A. X., Bernards, R., Qin, W., & Wang, C. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00704-9 · Cited by 747
Long, G. V., Swetter, S. M., Menzies, A. M., Gershenwald, J. E., & Scolyer, R. A. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00821-8 · Cited by 746
Drobni, Z. D., Alvi, R. M., Taron, J., Zafar, A., Murphy, S., Rambarat, P. K., Mosarla, R. C., Lee, C., Zlotoff, D. A., Raghu, V. K., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.049981 · Cited by 590
Metadata
- Authors
- Johnson, D. B., Sullivan, R. J., & Menzies, A. M.
- Affiliations
- Vanderbilt University Medical Center (US)
- Massachusetts General Hospital (US)
- The University of Sydney (AU)
- Corresponding author
- Johnson, Douglas B.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2017-02-27
- Volume
- 123
- Issue
- 11
- Pages
- 1904-1911
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- PMC
- PMC5445005
- OpenAlex
- W2592187743
- Cited by
- 339
- References
- 78
- Citations by year
- 2026: 10 · 2025: 30 · 2024: 21 · 2023: 32 · 2022: 42 · 2021: 58 · 2020: 71 · 2019: 42 · 2018: 23 · 2017: 10
- FWCI
- 4.19
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cancer (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (K23 CA204726)
- Cancer Institute NSW
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- immune checkpoint inhibitors, PD-1/PD-L1 pathway, underrepresented groups, autoimmune disease, organ transplant recipients, chronic viral infection, immunosuppressants, organ dysfunction, pregnancy, brain metastases, elderly patients, treatment safety, treatment efficacy
- MeSH terms
- Ipilimumab, Squamous Cell Carcinoma of Head and Neck, Nivolumab, Age Factors, Antibodies, Monoclonal, Antineoplastic Agents, Autoimmune Diseases, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Female, Graft Rejection, Head and Neck Neoplasms, Humans, Immunosuppressive Agents, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasms, Pregnancy, Pregnancy Complications, Neoplastic, HIV Infections, Immunocompromised Host, Hepatitis B, Chronic, Hepatitis C, Chronic, B7-H1 Antigen, CTLA-4 Antigen, Programmed Cell Death 1 Receptor, Transplant Recipients
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
